License, Collaboration & Royalty Revenue was Aurinia Pharmaceuticals’s largest product and service line in fiscal 2025, bringing in $11.71M of $23.41M (50%).
| Product and Service | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|
| Net Product Sales | $103.47M | $158.53M | $216.19M | — | ||||
| Product Revenue, Net | — | — | — | — | ||||
| Contract Revenue | — | — | — | — | ||||
| License & Collaboration Revenue | — | — | — | — | ||||
| License & Contract Revenue | — | — | — | — | ||||
| Licensing Revenue | — | — | — | — | ||||
| License, Collaboration & Royalty Revenue | $30.56M | $16.98M | $18.95M | $11.71M | ||||
| Service Revenue | $500.00K | — | — | $11.70M | ||||
| Total | $134.53M | $175.51M | $235.13M | $23.41M |
Aurinia Pharmaceuticals brought in $23.41M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. Aurinia Pharmaceuticals regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $235.13M. License, Collaboration & Royalty Revenue was the largest at $11.71M (50.0%), ahead of Service Revenue at $11.70M (50.0%).
Aurinia Pharmaceuticals stopped reporting Net Product Sales as a separate line after fiscal 2024, when it brought in $216.19M.
U.S was Aurinia Pharmaceuticals’s largest region in fiscal 2024, bringing in $210.10M of $235.13M (89%).
| Geography | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 |
|---|---|---|---|---|---|---|---|
| U.S | — | $102.46M | $157.96M | $210.10M | |||
| United States | $45.49M | — | — | — | |||
| Japan | — | $31.48M | $17.56M | $25.04M | |||
| China | — | — | — | — | |||
| Other | $117.00K | $89.00K | — | — | |||
| Total | $45.61M | $134.03M | $175.51M | $235.13M |
Aurinia Pharmaceuticals brought in $235.13M from its two regions in fiscal 2024, the year ended December 31, 2024. That was up 34.0% from $175.51M in fiscal 2023. U.S was the largest at $210.10M (89.4%), ahead of Japan at $25.04M (10.6%).
Compared with fiscal 2023, Japan grew 42.6% to $25.04M and U.S grew 33.0% to $210.10M.
Aurinia Pharmaceuticals began breaking out U.S in fiscal 2022, when it brought in $102.46M. Aurinia Pharmaceuticals stopped reporting United States ($45.49M in fiscal 2021) and Other ($89.00K in fiscal 2022) as separate regions.
United States was Aurinia Pharmaceuticals’s largest region in fiscal 2019, bringing in $200.00K of $318.00K (63%).
| Geography | FY 2018 | FY 2019 |
|---|---|---|
| United States | $345.00K | $200.00K |
| China | $118.00K | $118.00K |
| Total | $463.00K | $318.00K |
Aurinia Pharmaceuticals brought in $318.00K from its two regions in fiscal 2019, the year ended December 31, 2019. That was down 31.3% from $463.00K in fiscal 2018. United States was the largest at $200.00K (62.9%), ahead of China at $118.00K (37.1%).
Compared with fiscal 2018, China grew 0.0% to $118.00K, while United States fell 42.0% to $200.00K.
Aurinia Pharmaceuticals (AUPH) reports its revenue by product and service and by geography. In fiscal 2025, License, Collaboration & Royalty Revenue was its largest product and service line, bringing in $11.71M (50.0% of the total), followed by Service Revenue at $11.70M (50.0%).
License, Collaboration & Royalty Revenue was Aurinia Pharmaceuticals' largest product and service line in fiscal 2025, bringing in $11.71M, or 50.0% of the $23.41M total across its two product and service lines.
U.S was Aurinia Pharmaceuticals' largest region in fiscal 2024, bringing in $210.10M, or 89.4% of the $235.13M total across its two regions.
Japan grew faster than U.S in fiscal 2024, up 42.6% from $17.56M to $25.04M. U.S grew 33.0% to $210.10M.
Every figure comes from Aurinia Pharmaceuticals' annual financial filings, as reported. Each line keeps the name Aurinia Pharmaceuticals gives it, and years follow its fiscal calendar.
Aurinia Pharmaceuticals' revenue by product and service goes back to fiscal 2018, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.